1 / 1
Glepaglutide is a long-acting GLP-2 analog developed for the treatment of short bowel syndrome (SBS). It enhances intestinal absorption and growth, helping patients reduce dependence on parenteral nutrition.
Glepaglutide binds to the glucagon-like peptide-2 receptor (GLP-2R) in the gut, promoting:
Clinical studies have shown that Glepaglutide can increase intestinal function and improve quality of life in SBS patients.